Abstract:Background Primary Sjogren's syndrome (pSS) is a chronic, systemic autoimmune disorder characterized by inflammation of exocrine glands and functional impairment of the salivary and lacrimal glands [1]. The pathogenesis of pSS is complicated with many respects remaining elusive. Interleukin-27 (IL-27) is a new member of the IL-12 cytokine family. It is largely secreted by activated antigen-presenting cells, such as macrophages and dendritic cells (DCs). IL-27 participates in multiple autoimmune diseases by regulating T lymphocyte subsets. Recent studies showed that IL-27 was involved in anti-inflammatory functions in SS [2]. However, the underlying mechanism of IL-27 in SS is still unknown. Objectives In the present study, the changes of lymphocyte subsets were studied in Il-27 knock-out and wild-type pSS models and pSS patients for the purpose to explore the specific mechanism of IL-27 in pSS and provide the basis for clinical treatment. Methods The NOD mice, Il-27 knockout (Il-27–/–) mice, Il-27 knockout mice with recombinant IL-27 treatment were studied. The saliva flow rates, weight, weight of submandibular glands and spleens were detected. Murine submandibular glands were fixed and paraffin sections were used for hematoxylin and eosin staining. The lymphocyte subsets of spleens from experimental mice and the peripheral blood from pSS patients were measured by flow-cytometric assay. Results Compared to WT NOD mice, the saliva flow rates decreased significantly, and the indexes of submandibular glands and spleens increased significantly in Il-27–/– mice (Fig 1A-E). The histological results showed that the number of lymphocytic infiltrates in submandibular glands of WT NOD was lower than Il-27–/– mice (Fig 1F). The splenic-Treg cells decreased significantly, but the levels of splenic Th17 and B cells increased significantly in Il-27–/– mice. After IL-27 treatment, the saliva flow rates, submandibular glands, Treg and Th17 cells were partially reversed in Il-27–/– mice (Fig 1G-M). Consistent with above observations, the changes of Terg and Th17 cells in pSS patients showed similar pattern. The Th2, Tfh and plasma cells increased significantly, whilst the B cells decreased significantly in pSS patients (Fig 1N-T). Compared with healthy control, the serum IL-27 decreased in pSS patients. Conclusions In general, these findings indicated that IL-27 deficiency deteriorated the disease symptoms of pSS and resulted in changes of Th17/Treg balance. In addition, pSS patients showed similar lymphocyte imbalance. Our data suggested that IL-27 might play an important role on the development and pathogenesis of pSS through regulating lymphocyte subsets, and targeting IL-27 and Th17/Treg balance may be a new direction of pSS treatment. References Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood, 2012, 120(15): 3142–3151. Lee BH, Carcamo WC, Chiorini JA, et al. Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy. Arthritis Res Ther, 2012, 14(4): R172. Disclosure of Interest None declared

[Serum IL-21 Level in Patients with Primary Sjogren's Syndrome and Clinical Significance of IL-21].

Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sjogren's syndrome

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Effect of Chinese Herbal Medicines for Nourishing Yin, Supplementing Qi, and Activating Blood on Reproductive Endocrine Activity and Immune Functions in Patients with Primary Sjogren's Syndrome.

Serum immunogiobulin A and its clinical role in primary Sjogren's syndrome

OP0166 Il-27 Participates in Sjogren's Syndrome by Regulating Lymphocyte Subsets

Association between IL-7 and primary Sjögren's syndrome: A single-center study and a systematic scoping review

Association Between IFN-α and Primary Sjogren's Syndrome

[The Expression of Interferon-Alpha in Peripheral Blood of Patients with Primary Sjogren's Syndrome].

Biomarkers of Interstitial Lung Disease Associated with Primary Sjögren's Syndrome.

Interleukin-17 expression in salivary glands and peripheral blood of patients with primary Sjogren's syndrome

Clinical Significance of the Expression Levels of Serum Transforming Growth Factor-Β and CXC Type Chemokine Ligand 13 in Primary Sjogren's Syndrome Patients.

Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren's Syndrome.

Interleukin 17E Associates with Haematologic Involvement and Autoantibody Production in Primary Sjögren's Syndrome.

Expression of interleukin 27 in the sera of patients with Sj(o)gren's syndrome and its regulation on interleukin 10

Serum biomarker-based risk model construction for primary Sjögren's syndrome with interstitial lung disease

The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren's Syndrome

The relevance of anti-lymphocyte antibody with primary Sj(o)gren syndrome

Expression of Interleukin-17 in Primary Sjögren's Syndrome and the Correlation with Disease Severity: A Systematic Review and Meta-Analysis.

Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease

Clinical features of interstitial lung disease in primary Sj(o)gren's syndrome